GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Double-Crane Pharmaceutical Co Ltd (SHSE:600062) » Definitions » Sale Of Investment

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Sale Of Investment : ¥2,364 Mil (TTM As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is China Resources Double-Crane Pharmaceutical Co Sale Of Investment?

China Resources Double-Crane Pharmaceutical Co's sale of investment for the three months ended in Mar. 2024 was ¥242 Mil. It means China Resources Double-Crane Pharmaceutical Co gained ¥242 Mil from selling investments. China Resources Double-Crane Pharmaceutical Co's sale of investment for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,364 Mil.

Compared with last quarter (¥603 Mil in Dec. 2023 ), China Resources Double-Crane Pharmaceutical Co gained less money from selling investments in Mar. 2024 (¥242 Mil).


China Resources Double-Crane Pharmaceutical Co Sale Of Investment Historical Data

The historical data trend for China Resources Double-Crane Pharmaceutical Co's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Double-Crane Pharmaceutical Co Sale Of Investment Chart

China Resources Double-Crane Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,342.70 2,295.97 3,051.75 2,951.73 2,324.33

China Resources Double-Crane Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 202.50 454.75 1,063.74 603.35 241.76

China Resources Double-Crane Pharmaceutical Co Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,364 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resources Double-Crane Pharmaceutical Co Sale Of Investment Related Terms

Thank you for viewing the detailed overview of China Resources Double-Crane Pharmaceutical Co's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
Executives
Yu Shun Ting Director
Han Shuo senior management
Liu Zi Qin senior management
Fan Yan Xi senior management
Lu Wen Chao Directors, senior managers
Man Chao senior management
Ni Jun senior management
Feng Yi Director
Zheng Ze Ping Supervisors
Li Ying senior management

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Headlines

No Headlines